Treatment | Number | % |
Any active treatment within 6 months | ||
Yes | 2188 | 56.8 |
No | 1667 | 43.2 |
Surgery | ||
Resection | 411 | 10.7 |
Thoracotomy (not resectable) | 36 | 0.9 |
No surgery3-150 | 3408 | 88.4 |
Radiotherapy3-151 | ||
No radiotherapy | 2474 | 64.2 |
Radiotherapy to chest ⩾50 Gy3-152 | 106 | 2.7 |
Radiotherapy to chest <50 Gy3-154 | 1078 | 28.0 |
Radiotherapy to other sites only | 193 | 5.0 |
Chemotherapy3-160 | ||
SCLC (n=678)3-164 | ||
Single agent | 87 | 12.8 |
Combination | 337 | 49.7 |
No chemotherapy | 253 | 37.3 |
NSCLC (n=2071)3-161 | ||
Single agent | 88 | 4.2 |
Combination | 82 | 4.0 |
No chemotherapy | 1901 | 91.8 |
Not known (n=1106)3-163 | ||
Single agent | 11 | 1.0 |
Combination | 15 | 1.4 |
No chemotherapy | 1080 | 97.6 |
Entry into clinical trials | ||
Yes | 110 | 2.9 |
No | 3745 | 97.1 |
↵3-150 Includes 154 patients who only had a mediastinoscopy.
↵3-151 Four patients received unknown dose of radiotherapy to the chest.
↵3-152 One patient received both radiotherapy to the chest (dose ⩾50 Gy) and radiotherapy to another site.
↵3-154 97 patients received both radiotherapy to the chest (dose <50 Gy) and radiotherapy to another site.
↵3-160 Percentages are of cases with a particular cell type.
↵3-164 One patient with SCLC received chemotherapy but the regimen was not recorded.
↵3-161 Includes cases with a recorded histological type known not to be SCLC.
↵3-163 Includes cases with type not known or not recorded and those with no microscopic verification.